Clinical Scorecard: Biomarkers Expand Precision in CRC
At a Glance
| Category | Detail |
|---|---|
| Condition | Colorectal Cancer (CRC) |
| Key Mechanisms | Use of diagnostic, prognostic, and predictive biomarkers to guide therapy and surveillance. |
| Target Population | Patients with colorectal cancer. |
| Care Setting | Oncology and personalized medicine. |
Key Highlights
- Established biomarkers like KRAS/NRAS and BRAF mutations are critical for personalized CRC management.
- Emerging biomarkers include DNA methylation panels and circulating miRNAs.
- Multianalyte tests show promise in enhancing sensitivity for CRC detection.
- Liquid biopsy monitoring can detect resistance mutations before radiologic progression.
- Integration of multi-omics data is essential for robust prognostic stratification.
Guideline-Based Recommendations
Diagnosis
- Utilize noninvasive biomarkers such as stool- and blood-based assays for CRC detection.
Management
- Select therapies based on established predictive biomarkers like RAS mutations and MSI status.
Monitoring & Follow-up
- Employ serial evaluation of circulating markers like CEA and ctDNA for therapy personalization.
Risks
- Challenges include the need for large-scale validation trials and assay standardization.
Patient & Prescribing Data
Patients with varying stages of colorectal cancer.
Rechallenge with anti-EGFR therapy may benefit patients without RAS/BRAF mutations post-drug holiday.
Clinical Best Practices
- Incorporate multi-omics integration for comprehensive patient assessment.
- Educate clinicians and patients on the evolving landscape of CRC biomarkers.
- Focus on noninvasive screening technologies to improve early detection.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
